Mark Kotter, CEO

Cell ther­a­py start­up adds $100M+ to its cof­fers and some im­pres­sive names to its board of di­rec­tors CEO Mark Kot­ter says the last ma­jor rev­o­lu­tion in bio­phar­ma oc­curred around the 1980s, when an­ti­bod­ies — or, as some called them, an­ti­cancer “mag­ic bul­lets” — opened up the door for new ther­a­pies.

Now cell ther­a­py is hav­ing a very sim­i­lar mo­ment, he told End­points News, and some blue-chip in­vestors are giv­ing his cell cod­ing com­pa­ny $103 mil­lion to get be­hind it.

Kot­ter un­veiled the high-dol­lar Se­ries B round on Fri­day, with par­tic­i­pa­tion from Arch Ven­tures, Charles Riv­er Lab­o­ra­to­ries, Fore­site Cap­i­tal, Na­tion­al Re­silience, Meta­plan­et, Puhua Cap­i­tal and Ten­cent. The new cash builds on a $41.5 mil­lion Se­ries A round that at­tract­ed some in­ter­est­ing in­vestors last June, in­clud­ing Na­tion­al Can­cer In­sti­tute ex-chief Rick Klaus­ner, Arch’s Bob Nelsen and Fore­site Cap­i­tal CEO Jim Tanan­baum.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.